Compound 0056
Alternative Names: Compound-0056Latest Information Update: 11 Oct 2021
Price :
$50 *
At a glance
- Originator Protheragen
- Class Antipsoriatics; Small molecules
- Mechanism of Action VISTA stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Psoriasis
Highest Development Phases
- Preclinical Psoriasis
Most Recent Events
- 11 Oct 2021 Compound 0056 is available for licensing as of 11 Oct 2021. https://www.protheragen.com/available-projects/a-small-molecule-agonist-targeting-vista/
- 11 Oct 2021 Protheragen has patent protection for Compound 0056 before October 2021 (Protheragen's pipeline, October 2021)
- 11 Oct 2021 Pharmacodynamics data from preclinical trial in Psoriasis released by Protheragen before October 2021 (Protheragen's pipeline, October 2021)